Somewhat Favorable Press Coverage Somewhat Unlikely to Affect LivaNova (LIVN) Share Price

Media coverage about LivaNova (NASDAQ:LIVN) has trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. LivaNova earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.8346111167819 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of brokerages recently issued reports on LIVN. Zacks Investment Research upgraded LivaNova from a “hold” rating to a “buy” rating and set a $89.00 price target for the company in a report on Thursday, November 9th. BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research report on Tuesday, November 7th. Piper Jaffray Companies reissued a “buy” rating and issued a $85.00 target price on shares of LivaNova in a research report on Friday, November 3rd. Canaccord Genuity reissued a “hold” rating and set a $71.00 target price on shares of LivaNova in a research note on Wednesday, September 20th. Finally, Jefferies Group raised their price target on shares of LivaNova from $76.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $79.71.

Shares of LivaNova (LIVN) traded down $1.03 on Thursday, hitting $81.05. 267,900 shares of the company traded hands, compared to its average volume of 342,671. LivaNova has a fifty-two week low of $45.67 and a fifty-two week high of $88.56. The company has a quick ratio of 1.42, a current ratio of 2.03 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $3,960.00 and a P/E ratio of 21.61.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.17. The company had revenue of $309.70 million for the quarter, compared to the consensus estimate of $301.22 million. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period last year, the firm posted $0.78 EPS. equities research analysts expect that LivaNova will post 3.24 earnings per share for the current fiscal year.

In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $74.58, for a total transaction of $74,580.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Alfred J. Novak sold 2,000 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total value of $171,540.00. The disclosure for this sale can be found here. Insiders sold a total of 6,830 shares of company stock worth $569,350 in the last 90 days. 0.28% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at

About LivaNova

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply